Tetra Bio Pharma Inc TBPMQ

ARDS-003 is going to be a successful drug

[Savage97]

Called ARDS-003, Tetra’s synthetic drug is designed to treat sepsis and acute respiratory distress syndrome, life-threatening conditions triggered when the body’s immune system “goes rogue” in response to an infection such as COVID-19 and begins attacking healthy cells as well as harmful bacteria and viruses. Chamberland says the drug effectively blunts the severity of the exaggerated immune response that often occurs in patients suffering from COVID-19, cancer and other diseases, thereby reducing the likelihood of deadly consequences such as sepsis and ARDS. 

"After 12 years of research, we’re pretty confident this is going to be a successful drug."

Guy Chamberland - CEO of Tetra Bio-Pharma

With the opportunity it’s been chasing for years now within reach, Chamberland says Tetra has all the pieces in place to start mass-producing ARDS-003 as soon as it gets the green light for emergency use from regulators in Canada and the U.S.  Meanwhile, he expects demand for ARDS-003 will only increase even after the current health crisis abates.

While COVID-19 presents the most obvious and immediate use case for the drug, Chamberland notes that sepsis and ARDS will remain global health threats long after the novel coronavirus is contained. Sepsis alone kills more than 14,000 Canadians a year and millions of people around the world.

“Other viruses are going to come,” he adds. “As a society, we have to be ready.” 

$$$
 

[SamV21]

Approximately 40+ key companies are developing Sepsis therapies. These companies are Cidara Therapeutics, Vivacelle Bio, Shaperon, Karyopharm Therapeutics, SciClone Pharmaceuticals, Asahi Kasei Pharma, Sanofi, Shionogi, Revimmune, Inotrem, Enlivex Therapeutics, Abionyx, and others have their Sepsis drug candidates in the under different phases of clinical development.

[JACKTHEBEAR2]

If we could only answer the single most important question WHEN

[Davesnothere]